TEKMIRA PHARMACEUTICALS CORP (TKMR)
(Delayed Data from NSDQ)
$10.83 USD
+0.58 (5.66%)
Updated Jul 31, 2015 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Arbutus Biopharma Corporation [TKMR]
Reports for Purchase
Showing records 1 - 20 ( 40 total )
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Q1/15 Results In Line With Our Estimates; Lots of Moving Parts 2H/15.
Provider: Clarus Securities
Analyst: NOVAK D
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
2014 In Line with our Estimates; Compelling BUY for 2015.
Provider: Clarus Securities
Analyst: NOVAK D
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
TKM-Ebola-Guinea, A Highly Strategic Asset, Commences Phase II Clinical Study
Provider: Clarus Securities
Analyst: NOVAK D
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
MONDAYS UNDER THE MICROSCOPE - Canadian Healthcare - Biotechnology Weekly Update
Provider: Clarus Securities
Analyst: NOVAK D
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Merger Positions Tekmira As The Most Attractive Early Stage Hepatitis B Play
Provider: Clarus Securities
Analyst: NOVAK D
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Merger Positions Tekmira As The Most Attractive Early Stage Hepatitis B Play.
Provider: Clarus Securities
Analyst: NOVAK D
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Remains On Track To Deliver Multiple Value Drivers in 2015
Provider: Clarus Securities
Analyst: NOVAK D